Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- ILa | -.--% | -0,67% | -16,62% |
08/05 | Indaptus Therapeutics, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 | CI |
14/03 | Top stijgers op de premarket | MT |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 24-02-21 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 03-08-21 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 01-07-21 |
Roger Waltzman
CTO | Chief Tech/Sci/R&D Officer | 56 | 07-08-23 |
Walt Linscott
COO | Chief Operating Officer | 63 | 01-07-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 03-08-21 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 03-08-21 |
Robert Martell
BRD | Director/Board Member | 61 | 13-01-23 |
Hila Karah
BRD | Director/Board Member | 55 | 01-07-21 |
Michael Newman
FOU | Founder | 68 | 24-02-21 |
Roger Pomerantz
CHM | Chairman | 67 | 01-08-21 |
Director/Board Member | 71 | 01-07-21 | |
Mark Gilbert
BRD | Director/Board Member | 63 | 01-11-21 |
Bedrijfsgegevens
Sector
- Beurs
- Aandelen
- Koers INDP
- Koers NTEC
- Onderneming Intec Pharma Ltd